Atlas Venture closed a $400 million Opportunity Fund aimed at supporting follow-on financing for its existing portfolio companies amid ongoing fundraising challenges in the biotech sector. The fund targets startups previously backed by Atlas to help them advance drug development programs amid a competitive landscape. This marks Atlas’s third Opportunity Fund, highlighting continued commitment to seed-led venture creation and tailored investment strategies. Prior portfolio companies include Mariana Oncology and Aiolos Bio.